Podcast

Examining Major Breakthroughs Made in Breast Cancer in Milwaukee

Author(s):

We traveled to Milwaukee, Wisconsin, for a State of the Science Summit™ on Breast Cancer, which featured insights from key thought leaders at Carbone Cancer Center of the University of Wisconsin.

We recently traveled to Milwaukee, Wisconsin, for a State of the Science Summit™ on Breast Cancer. At the meeting, faculty from Carbone Cancer Center of the University of Wisconsin highlighted the evolving paradigms across breast cancer subtypes and settings, such as early and advanced hormone receptor—positive breast cancer, early-stage HER2-positive breast cancer, and metastatic triple-negative breast cancer.

Related Videos
Ruth M. O’Regan, MD
Peter Forsyth, MD
David Rimm, MD, PhD, discusses current HER2 immunohistochemistry assays that are used in the management of breast cancer, and their shortcomings.
Nancy U. Lin, MD, discusses the safety data from DESTINY-Breast12 with T-DXd for HER2+ advanced/metastatic breast cancer with or without brain metastases.
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Sheldon M. Feldman, MD
Sheldon M. Feldman, MD
Dana Zakalik, MD
Alberto Montero, MD, MBA, CPHQ
Jairam Krishnamurthy, MD, FACP